Paul Hudson, CEO of Sanofi, has been driving an all-encompassing effort to use AI to reshape the way the company ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong ...

Regeneron-partnered Dupixent, the crown jewel of Sanofi’s commercial portfolio, continued to impress with 21.1% sales growth ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, 2025 outlook, drug pipeline, the company's dividend and buyback decision, his thoughts on the ...

For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.

Sanofi CEO Paul Hudson speaks during the Competing In The Global Marketplace: Strategies for Growth panel, at the Fortune Global Forum on Nov. 11, 2024 in New York City. (Jemal Countess—Getty ...

Paul Hudson, CEO of Sanofi, works in a volatile business. The pharma sector has been very profitable for many decades, and its weight in the economy has grown steadily.

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, drug pipeline outlook, the company's Dupixent drug, and more. U.S. Bank says it believes its vice ...

Sanofi CEO Paul Hudson on the potential for AI to drive insights and better decision intelligence in the pharmaceutical industry.

PARIS—Sanofi’s newly installed CEO Paul Hudson asked journalists to turn an objective eye on the company—and, presumably, him—as he tunes up strategy, sets priorities and generally figures ...

Sanofi (NASDAQ:SNY) 39th Annual JPMorgan Virtual Healthcare Conference January 12, 2021 11:40 AM ETCompany ParticipantsPaul Hudson - CEOArnaud Robert - ...